News | November 03, 2007

Alternative Treatment in STEMI Patients Undergoing PCI Looks Promising

November 4, 2007 – A specific way of dosing eptifibatide appears equally effective as giving abciximab as an adjunct to primary percutaneous coronary intervention (PCI) in restoring blood flow to the heart, according to late-breaking clinical trial results announced at the American Heart Association’s Scientific Sessions 2007.

The EVA-AMI study (Eptifibatide Versus Abciximab in Primary PCI for Acute ST elevation Myocardial Infarction) compared the effectiveness of giving a double bolus of eptifibatide versus abciximab in achieving complete electrocardiographic ST resolution 60 minutes after PCI. (Complete ST resolution means a greater than 70 percent resolution of the ST segment elevation seen on the patient’s initial electrocardiogram.) Standard treatment after a heart attack often includes PCI, or angioplasty, to re-open the blocked artery that caused the attack. After PCI, patients are typically prescribed medicine to reduce the risk of blood clots. The drugs eptifibatide and abciximab are both glycoprotein IIb/IIIa inhibitors, which prevent platelets from sticking together to form blood clots.

“Complete ST resolution is a sign that blood is getting through to the heart muscle. It is closely related to 30-day and long-term mortality,” said Uwe Zeymer, lead author of the study, which was conducted out of Ludwigshafen, Germany. “Our results show there were no differences between the effectiveness of the two drugs.”

EVA-AMI is an international, multicenter, randomized, prospective, open parallel group comparison of the two drugs in patients undergoing primary PCI less than 12 hours after having a heart attack. The study included 430 patients in France and Germany between November 2006 and May 2007.

The patients were also taking clopidogrel (another antiplatelet) and aspirin, plus heparin (a blood thinner) or enoxaparin (a low molecular weight heparin), which are all part of standard treatment after a heart attack.

Support for this study was provided by Glaxo Smith Kline.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The American Heart Association makes no representation or warranty as to their accuracy or reliability.

For more information: www.americanheart.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init